Cagrilintide
Price range: $ 49.00 through $ 89.00
All products are for laboratory research purposes only. Not for human consumption, medical, or veterinary use. ION Peptides does not condone or support the use of peptides outside of controlled scientific research. By purchasing, you acknowledge that you are a qualified researcher or institution. You must be 21 or older.
Cagrilintide
Research-Grade Amylin Analogue
Tagline: Appetite & Weight Regulation Research
Product Description
Cagrilintide is a long-acting amylin analogue designed for once-weekly administration in research models. It mimics the effects of endogenous amylin, a hormone co-secreted with insulin from pancreatic β-cells, and plays a key role in satiety signaling, gastric emptying regulation, and weight management.
Researchers use cagrilintide to investigate appetite control, energy balance, obesity treatment strategies, and combination therapies with GLP-1 receptor agonists.
For Laboratory and Scientific Research Use Only. Not for Human Consumption.
Why Researchers Choose Cagrilintide
Long-Acting Amylin Analogue: Engineered with prolonged half-life for sustained activity.
Appetite Suppression Studies: Potently reduces food intake in preclinical models.
Weight Regulation Research: Promotes negative energy balance and body fat reduction.
Combination Therapy Applications: Studied alongside semaglutide for additive metabolic effects.
Batch Verified: ≥98% purity, HPLC-tested for reproducibility.
Important Note
For laboratory and scientific research only. Not for human consumption, therapeutic, or diagnostic use.
| Chemical Formula | C₁₇₇H₂₆₉N₄₇O₅₃S |
| Molecular Mass | ~3791 Da |
| CAS Number | 1419995-32-2 |
| Form | Lyophilized peptide powder |
| Shelf Life | 24 months (lyophilized) |
| Handling | Protect from light; avoid repeated freeze-thaw cycles |
| Intended Use | For preclinical and in vitro research only |
| Storage | -20 °C (dry powder), -80 °C (after reconstitution) |
Research Applications
Appetite & Satiety Studies
Cagrilintide reduces food intake by activating amylin receptors in the area postrema and nucleus tractus solitarius [1].
Weight Management Research
Shown to induce dose-dependent weight loss and fat mass reduction in rodent and primate models [2].
Gastric Emptying Regulation
Delays gastric emptying, contributing to improved postprandial glucose control [3].
Combination Therapy with GLP-1 Analogues
Co-administered with semaglutide for additive effects on weight reduction and appetite suppression [4].
References
Gabery S et al. (2020). Cagrilintide, a Long-Acting Amylin Analogue: CNS Target Engagement. Diabetes Obes Metab.
https://insight.jci.org/articles/view/133429/sd/1Nauck MA et al. (2021). Weight-Loss Effects of Cagrilintide in Obesity Research. Lancet.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2901751-7/fulltextHay DL et al. (2015). Amylin Receptor Pharmacology and Gastric Emptying. Br J Pharmacol.
https://docslib.org/doc/978634/amylin-pharmacology-physiology-and-clinical-potentialFriedrichsen M et al. (2021). Cagrilintide Plus Semaglutide: Combination Therapy Research. Lancet.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2900944-2/fulltext
Mechanism of Action (How Cagrilintide Works)
Amylin Receptor Agonism: Binds to calcitonin receptor/RAMP complexes in the brainstem, activating satiety signaling [Gabery 2020].
Food Intake Suppression: Reduces meal size and frequency via CNS-mediated anorectic pathways [Nauck 2021].
Delayed Gastric Emptying: Slows gastric motility, improving postprandial glucose handling [Hay 2015].
Weight Loss Promotion: Induces negative energy balance by lowering caloric intake and enhancing energy expenditure [Nauck 2021].
Additive with GLP-1 RAs: Complements GLP-1 receptor agonist effects, resulting in greater weight loss when combined [Friedrichsen 2021].
References
Gabery S et al. (2020). Cagrilintide, a Long-Acting Amylin Analogue: CNS Target Engagement. Diabetes Obes Metab.
https://insight.jci.org/articles/view/133429/sd/1Nauck MA et al. (2021). Weight-Loss Effects of Cagrilintide in Obesity Research. Lancet.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2901751-7/fulltextHay DL et al. (2015). Amylin Receptor Pharmacology and Gastric Emptying. Br J Pharmacol.
https://docslib.org/doc/978634/amylin-pharmacology-physiology-and-clinical-potentialFriedrichsen M et al. (2021). Cagrilintide Plus Semaglutide: Combination Therapy Research. Lancet.
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2821%2900944-2/fulltext
